IP Library Granted Patent US 8,916,166
Granted Patent B2
US 8,916,166 · App. 13/547,556 · Granted Dec 23, 2014

Patent

Inventors: Stuart Geoffrey Dashper (Victoria, AU); Ching Seng Ang (Victoria, AU); Paul David Veith (Victoria, AU); Eric Charles Reynolds (Victoria, AU)
Assignee: Oral Health Australia Pty Ltd
A61K39/0216A61K38/164C07K14/195A61K39/00G01N2333/195G01N2800/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,166
App. No.
13/547,556
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of periodontal disease. In particular, two specific internalin-like P. gingivalis proteins, namely PG0350 and PG1374 involved in the internalization of P. gingivalis by host cells, the hypothetical protein, PG1019 purported to be a cell surface lipoprotein and the alkyl hydroperoxide reductase protein, PG0618 have been identified as useful targets for the prevention and treatment of periodontal disease.

Claims (8)

1. A method of treating a subject having a P. gingivalis infection and/or periodontal disease comprising administering to the subject a composition comprising (a) an effective amount of a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 or a variant of SEQ ID NO: 3 consisting of conservative amino acid substitutions to SEQ ID NO: 3 that is at least 90% identical to SEQ ID NO: 3, wherein the variant polypeptide induces the production of an antibody that specifically binds to the polypeptide of SEQ ID NO:3 and (b) a pharmaceutically acceptable carrier.

2. The method according to claim 1 , wherein the composition comprises said variant polypeptide at least 90% identical to SEQ ID NO: 3.

3. The method according to claim 1 , wherein the composition comprises a variant polypeptide that is at least 95% identical to SEQ ID NO: 3.

4. The method according to claim 1 , wherein the composition comprises a variant polypeptide that is at least 96% identical to SEQ ID NO: 3.

5. The method according to claim 1 , wherein the composition comprises a variant polypeptide that is at least 97% identical to SEQ ID NO: 3.

6. The method according to claim 1 , wherein the composition comprises a variant polypeptide that is at least 98% identical to SEQ ID NO: 3.

7. The method according to claim 1 , wherein the composition comprises a variant polypeptide that is at least 99% identical to SEQ ID NO: 3.

8. The method according to claim 1 , wherein the composition comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:3.

Priority Claims (1)
AU 2006903425 · Jun 27, 2006 · national
Continuity (2)
Division 12306495
Related Publication 20130236488A1 · Sep 12, 2013